Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas

NCT02859857 is registered in ClinicalTrials.gov with Bexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02859857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Lead sponsor
Bexion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2016
Completion date
June 15, 2020
Enrollment
86 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms